The U.S. Food and Drug Administration (FDA) in White Oak, Md., on June 5, 2023. Madalina Vasiliu/The Epoch Times

Moderna’s messenger ribonucleic acid (mRNA) influenza vaccine is effective, but uncertainties remain, Food and Drug Administration reviewers said in a document released on June 16.

Data from a Phase 3 trial show the mRNA vaccine, known as mRNA-1010, had a “clinical benefit,” the reviewers said in the 92-page document.

We had a problem loading this article. Please enable javascript or use a different browser. If the issue persists, please visit our help center.